P3781
An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 RearrangementA Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibCeritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLCStudy of Ceritinib in Patients With Unresectable MelanomaA Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 RearrangementPhase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-Small Cell Lung Cancer (The NCI-NRG ALK Master Protocol)MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS
P4844
New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinibPersonalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for CeritinibCeritinib for ALK-Rearrangement-Positive Non-Small Cell Lung CancerCeritinib for the treatment of late-stage (metastatic) non-small cell lung cancerThe ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung CancerCeritinib in ALK-rearranged non-small-cell lung cancer.I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.Ceritinib: A primer for pharmacists.Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.Ultrafast quantitative MS-based method for ceritinib analysis in human plasma samples from clinical trial.Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.Zykadia (Ceritinib) Approved for Patients with Crizotinib-Resistant ALK -Positive Non-Small-Cell Lung Cancer.P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung CancerEffect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.Synthesis of a [(18)F]-labeled ceritinib analogue for positron emission tomography of anaplastic lymphoma kinase, a receptor tyrosine kinase, in lung cancer.Alectinib, Ceritinib, Elotuzumab, and Venetoclax.Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer.Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.Ceritinib: first global approval.ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?Ceritinib for the treatment of non-small cell lung cancer.Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer.Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset.Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond.The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Ceritinib
@es
ceritinib
@cs
ceritinib
@en
ceritinib
@fr
سيريتينيب
@ar
セリチニブ
@ja
色瑞替尼
@zh
type
label
Ceritinib
@es
ceritinib
@cs
ceritinib
@en
ceritinib
@fr
سيريتينيب
@ar
セリチニブ
@ja
色瑞替尼
@zh
altLabel
Ceritinib
@en
LDK378
@en
N-{2-[(5-chloro-2-{[2-isopropo ...... o]phenyl}propane-2-sulfonamide
@en
NVP-LDK378-NX
@en
Zykadia®
@en
compound 15b [PMID 23742252]
@en
céritinib
@en
prefLabel
Ceritinib
@es
ceritinib
@cs
ceritinib
@en
ceritinib
@fr
سيريتينيب
@ar
セリチニブ
@ja
色瑞替尼
@zh